PMC Inpatients Jan-June 2011
Antimicrobial Agent Abbreviations  
 
Amp- Ampicilin, Amox/Clav- Amoxicillin/Clavulanate, Amp/Sulb-Ampicillin/Sulbactam, Amik- Amikacin, Aztre-Aztreonam, Cefaz- Cefazolin, Ceftaz-Ceftazidime, Cefep-Cefepime, Chloro-Chloramphenicol, Clinda-Clindamycin, Eryth-Erythromycin, Gent-Gentamicin, Imip-Imipenem, Levo-Levofloxacin,Linz-Linezolid, Mero-Meropenem, Nitro-Nitrofurantoin, Norflox- Norfloxacin, Naf-Nafcillin, Pen-Penicillin, Pip/Tazo-Pipercillin/Tazobactam, Quin-Dalf-Quinupristin-Dalfopristin, Tetra-Tetracycline, Tmp/Sxt- Trimethoprim/Sulfamethoxazole, Tobra-Tobramycin, Vanco-Vancomycin  
 
 
 
PMC Inpatients, Jan-June 2011, Blood Isolates    
  Percent Susceptible  
Organism No Amp or Pen Amp/Sulb Cefaz Clinda Eryth Gent(Strep) Naf Tmp/Sxt Levo Tetra Linz Quin-Dalf Vanco  
S. aureus 95 2 53 53 53 42 98 52 98 60 97 100 100 100  
Staphylococcus epi 33 0 33 33 46 36 82 33 nt 27 91 100 100 100  
Enterococcus sp 31 52 nt R** R** nt 84hl (60hl) nt R** 23 13 100 nt 61  
** intrinsic resistance *hl- high level gentamicin, 500 ug/ml, high level streptomycin, 2000 ug/ml, in parenthesis    
 
 
  Percent Susceptible  
Organism No. Amp Amp/Sulb or Amox/Clav Cefaz Ceftaz Cefep Gent Tobra Amik Levo Pip (Pip/Tazo) Tmp/Sxt Mero  
E. coli 25 48 80 61 88 96 84 88 100 60 48(100) 60 100  
       
 
PMC Inpatients, Jan-June, 2011 Non-Urinary Isolates  
    Percent Susceptible  
Organism No Amp or Pen Cefaz Clinda Ery Gent Naf Tmp/Sxt Levo Tetra Linz Nitro Quin-Dalf Vanco  
S. aureus 323 1 50 57 32 98 50 95 55 92 100 99 100 100  
Staphylococcus epidermidis 11 0 46 36 36 46 46 nt 55 100 100 100 100 100  
Enterococcus sp 85 74 R** nt nt nt nt R** 51 20 100 nt nt 73  
** intrinsic resistance  
 
 
Organism No. Amp Amp/Sulb or Amox/Clav Cefaz Ceftaz Cefep Gent Tobra Amik Levo Mero Pip (Pip/Tazo) Tmp/Sxt  
E. cloacae 15 R** R** R** 73 93 100 100 100 100 100 67(73) 93  
E. coli 52 31 69 48 90 92 81 77 100 37 100 37(91) 56  
K. pneumoniae 28 R** 50 24 46 61 50 54 79 54 68 0(43) 46  
M. morganii 10 0 0 0 90 100 100 100 100 80 100 80(100) 80  
P. mirabilis 15 87 87 75 100 93 93 87 100 73 100 87(100) 80  
P. aeruginosa 64 R** R** R** 78 86 61 83 95 60 69 77 R**  
S. marcescens 10 R** R** R** 100 100 100 100 100 100 100 90(90) 100  
** intrinsic resistance    
 
PMC Inpatients, Jan-June 2011, Urinary Isolates    
    Percent Susceptible  
Organism No Amp or Pen Cefaz Ery Clinda Gent Naf Nitro Tmp/Sxt Levo Tetra Linz Quin-Dalf Vanco  
S. aureus 22 0 64 55 64 95 64 100 91 50 96 100 100 100  
Staphylococcus, coag neg 51 0 47 47 65 75 47 100 nt 82 82 100 100 100  
Enterococcus sp 141 72 R** nt nt nt nt 71 R** check 25 100 nt 72  
** intrinsic resistance  
 
 
  Percent Susceptible  
Organism No. Amp Amp/Sulb or Amox/Clav Cefaz Ceftaz Cefp Gent Tobra Amik Levo Norflox Nitro Pip (Pip/Tazo) Tmp/Sxt Tetra Mero
E. coli 189 46 78 81 94 94 89 92 100 59 59 95 48(100) 71 74 100
K. pneumoniae 45 R** 80 67 67 76 78 71 87 78 69 36 0(83) 64 80 87
P. mirabilis 25 88 92 84 100 100 88 92 100 52 64 0 88(100) 80 0 nt
P. aeruginosa 22 R** R** R** 100 100 82 100 100 68 nt nt 95 nt nt 100
** intrinsic resistance